UroToday

EAU 2026: Final Analysis of the Phase 1 First-in-Human Study of an Erdafitinib Intravesical Drug-Releasing System in Patients with NMIBC Harboring Select FGFR A…

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
UroToday

EAU 2026: Development of a Novel 68Ga-Labeled Radiotracer Targeting Carbonic Anhydrase IX for Diagnosis of Clear Cell Renal Cell Carcinoma

The CAIX targeting radiotracer 68 Ga-C1 was developed and validated through in vitro assays. Initially, the investigators ...
UroToday

EAU 2026: [89Zr]Zr-girentuximab PET/CT in the Non-invasive Characterization of Indeterminate Renal Lesions: Initial Real-world Clinical Experience

The PET tracer [ 89 Zr]Zr-girentuximab targets carbonic anhydrase IX (CAIX), a hypoxia-inducible enzyme that is strongly expressed in clear cell renal cell carcinoma (ccRCC). CAIX expression is highly ...
UroToday

EAU 2026: Impact of 89Zr-girentuximab PET Versus Conventional Imaging on Clinical Decision-making in Patients with Indeterminate Renal Masses (ZIRCON-X)

Annual Congress was host to a renal cell carcinoma abstract session. Dr. David Liu presented results from ZIRCON-X, a post-hoc analysis of the phase 3 ZIRCON study evaluating the potential impact of ...
UroToday

EAU 2026: CAPTAIN: Randomized Controlled Trial Evaluating MRI-Guided TULSA Versus Robotic Prostatectomy – Initial Perioperative Outcomes

The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation by Dr. Laurence Klotz discussing initial perioperative outcomes of CAPTAIN, ...
UroToday

EAU 2026: Comparative Effectiveness of NAI +BCG versus Other Bladder-Sparing Therapies in BCG-Unresponsive NMIBC with CIS ± Ta/T1 Papillary Disease: An External Control Arm Study

After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
UroToday

EAU 2026: Safety and Skeletal Event Profile of Radium-223 Combined with Enzalutamide in mCRPC: A Multicenter Retrospective Analysis in Japan

Grade ≥3 hematologic toxicities were uncommon (anemia 6.1%, neutropenia 5.2%), and non-hematologic adverse events were rare. The absence of bone-modifying agents was the strongest predictor of ...
UroToday

EAU 2026: Time-Dependent Survival Benefit of Enzalutamide + Radium-223 in mCRPC: Reconstructed Analysis of the PEACE-3 Trial

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...
UroToday

EAU 2026: Optimizing the Timing of Docetaxel After Androgen Receptor Pathway Inhibitor Therapy: Development and Validation of a Novel Prognostic Model in mCR…

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...
UroToday

EAU 2026: Debate: Optimal Management of De-Novo Oligometastatic Disease: Radiotherapy – Treat All You Can See

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...
UroToday

EAU 2026: External Validation of a Prognostic Risk Model for Overall Survival After Radium-223 Treatment in mCRPC

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr ...
UroToday

EAU 2026: ARTO Trial: Long-Term Overall Survival Analysis from a Randomized Phase II Trial Testing the Benefit of SBRT Addition to Abiraterone in Oligometastatic CRPC Patients

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr. Giulio ...